featured
2023 Top Story in Metastatic Breast Cancer: Kicking the Can Down the Road—Delaying the Use of Chemotherapy in Hormone Receptor–Positive Metastatic Breast Cancer With Novel Endocrine and Targeted Treatment Options
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246-3256.
- Oliveira M, Pominchuk D, Nowecki Z, et al. GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Paper presented at: 2022 San Antonio Breast Cancer Symposium; December 6–10, 2022; San Antonio, TX. Abstract GS3-02.
- Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070.
Disclosure statements are available on the authors' profiles: